Actively Recruiting
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Led by University of Oxford · Updated on 2025-09-22
300
Participants Needed
2
Research Sites
730 weeks
Total Duration
On this page
Sponsors
U
University of Oxford
Lead Sponsor
B
Bournemouth University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer. Background: People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions and risk factors that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with the viruses hepatitis B and C. One of the concerns about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance for liver cancer) so that if a cancer develops, it is diagnosed at an early stage when it can be cured. However, ultrasound can miss cancers even in people having scans every 6 months. Furthermore, the risk of cancer is not alike among people with cirrhosis. For example, people with more advanced cirrhosis and those with cirrhosis from hepatitis B are at higher risk. It is therefore possible that better tests than ultrasound are needed for people with cirrhosis who are at particularly high risk of developing cancer. Computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans with dye injection (contrast) are used for liver cancer diagnosis. However, they cannot be done every 6 months because of costs, capacity and toxicity from high CT radiation doses, and MRI contrast build-up in the brain with repeated MRI contrast injections. MRI scans without contrast are not toxic, could be done in 20 minutes and are cheaper, so could be done every 6 months. In the experience of the study investigators, MRI without contrast may raise suspicion of liver cancer in cases missed by ultrasound, so it could be used for surveillance instead of ultrasound. This study aims to find out if it is feasible to use a quick MRI (20 minutes) without contrast as surveillance for liver cancer in people at high risk of liver cancer due to liver cirrhosis and to compare this MRI with ultrasound. Design and Methods: The investigators will recruit 300 people at higher risk of developing liver cancer because of cirrhosis. Study participants will have an ultrasound scan every 6 months as they would in their standard clinical care and an additional 6 monthly non-contrast MRI scan for 30 months (6 visits). If the ultrasound or non-contrast MRI raises concern for a possible liver cancer, an MRI scan with contrast (with dye injection) will be done for definitive diagnosis. All participants will have an MRI with contrast at the end of 30 months (M30) to ensure that no cancers were missed. Participants will be asked to complete questionnaires to measure quality of life, anxiety, and their experience of MRI and ultrasound scans and data will be collected from their medical notes. The number of liver cancers detected by ultrasound will be compared to the number detected by the non-contrast MRI scans.
CONDITIONS
Official Title
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to give informed consent for participation
- All genders aged 18 years or older
- Eligible for liver cancer ultrasound surveillance as determined by local investigators
- Child Pugh score of A or B
- Diagnosed with liver cirrhosis due to alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, chronic hepatitis C, chronic hepatitis B, or genetic haemochromatosis
- Have an annual liver cancer risk of at least 3% based on the aMAP score OR
- Have chronic liver disease (with or without cirrhosis), successfully treated for liver cancer with no recurrence, and returned to 6-monthly ultrasound surveillance
You will not qualify if you...
- Contraindications to MRI
- Known allergy or reaction to intravenous gadolinium contrast
- Prisoners
- Pregnant or breastfeeding
- Previous liver transplant
- Known indeterminate liver nodules on prior imaging requiring ongoing MRI or CT follow-up
- Previous liver cancer treated with curative intent and still followed with contrast CT or MRI for recurrence
- Estimated glomerular filtration rate below 30 ml/min/1.73m2
- On haemodialysis
- Unlikely to comply with study procedures as judged by local investigator
- Co-morbidity likely to cause death within 12 months as judged by clinician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Oxford University Hospitals NHS Foundation Trudt
Oxford, Oxon, United Kingdom, ox3 9du
Actively Recruiting
2
Bournemouth University Hospital
Bournemouth, United Kingdom
Actively Recruiting
Research Team
M
Michael Pavlides, DPhil
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here